117 related articles for article (PubMed ID: 17867295)
1. [Continuous infusion of cyclosporine A and C3 monitoring in pediatric stem cell transplantation].
Matsubara H; Kobayashi M; Yui Y; Kato I; Niwa A; Arai M; Miyazaki M; Mizushima Y; Umeda K; Hiramatsu H; Watanabe K; Adachi S; Nakahata T
Rinsho Ketsueki; 2007 Aug; 48(8):605-10. PubMed ID: 17867295
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Shibuya Y; Kato M; Takahashi M; Miura I
J Clin Pharm Ther; 2011 Aug; 36(4):518-24. PubMed ID: 21105879
[TBL] [Abstract][Full Text] [Related]
3. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor.
Kanda Y; Hyo R; Yamashita T; Fujimaki K; Oshima K; Onoda M; Mori T; Sakura T; Tanaka M; Sakai M; Taguchi J; Kurakawa M; Maruta A; Okamoto S; Sakamaki H;
Am J Hematol; 2006 Nov; 81(11):838-44. PubMed ID: 16888784
[TBL] [Abstract][Full Text] [Related]
4. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.
Oshima K; Kanda Y; Nakasone H; Arai S; Nishimoto N; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Mar; 83(3):226-32. PubMed ID: 17918253
[TBL] [Abstract][Full Text] [Related]
5. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
6. [Comparative study on the efficacy and safety of continuous versus twice-daily 3-hour infusion of cyclosporine A in pediatric hematopoietic stem cell transplantation].
Nodomi S; Umeda K; Matsubara H; Daifu T; Kato I; Hiramatsu H; Watanabe K; Heike T; Adachi S
Rinsho Ketsueki; 2012 Nov; 53(11):1891-7. PubMed ID: 23257669
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.
Izumi N; Furukawa T; Sato N; Okazuka K; Tsukada N; Abe T; Yano T; Kurasaki T; Masuko M; Toba K; Takahashi M; Aizawa Y
Bone Marrow Transplant; 2007 Nov; 40(9):875-80. PubMed ID: 17724440
[TBL] [Abstract][Full Text] [Related]
8. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.
Schrauder A; Saleh S; Sykora KW; Hoy H; Welte K; Boos J; Hempel G; Grigull L
Pediatr Transplant; 2009 Jun; 13(4):444-50. PubMed ID: 18482216
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients.
Hendriks MP; Blijlevens NM; Schattenberg AV; Burger DM; Donnelly JP
Bone Marrow Transplant; 2006 Oct; 38(7):521-5. PubMed ID: 16981000
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Barkholt L; Remberger M; Bodegård H; Ringdén O; Böttiger Y
Bone Marrow Transplant; 2007 Oct; 40(7):683-9. PubMed ID: 17660840
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.
Kimura S; Oshima K; Okuda S; Sato K; Sato M; Terasako K; Nakasone H; Kako S; Yamazaki R; Tanaka Y; Tanihara A; Higuchi T; Nishida J; Kanda Y
Bone Marrow Transplant; 2010 Jun; 45(6):1088-94. PubMed ID: 19898510
[TBL] [Abstract][Full Text] [Related]
13. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
[TBL] [Abstract][Full Text] [Related]
14. Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation.
Duncan N; Arrazi J; Nagra S; Cook M; Thomson AH; Craddock C
Ther Drug Monit; 2010 Jun; 32(3):353-8. PubMed ID: 20224513
[TBL] [Abstract][Full Text] [Related]
15. Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients.
Choi JS; Lee SH; Chung SJ; Yoo KH; Sung KW; Koo HH
Bone Marrow Transplant; 2006 Jul; 38(1):29-35. PubMed ID: 16715103
[TBL] [Abstract][Full Text] [Related]
16. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
17. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion.
Ogawa N; Kanda Y; Matsubara M; Asano Y; Nakagawa M; Sakata-Yanagimoto M; Kandabashi K; Izutsu K; Imai Y; Hangaishi A; Kurokawa M; Tsujino S; Ogawa S; Aoki K; Chiba S; Motokura T; Hirai H
Bone Marrow Transplant; 2004 Mar; 33(5):549-52. PubMed ID: 14716350
[TBL] [Abstract][Full Text] [Related]
18. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
[TBL] [Abstract][Full Text] [Related]
19. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.
Umeda K; Adachi S; Tanaka S; Ogawa A; Hatakeyama N; Kudo K; Sakata N; Igarashi S; Ohshima K; Hyakuna N; Chin M; Goto H; Takahashi Y; Azuma E; Koh K; Sawada A; Kato K; Inoue M; Atsuta Y; Takami A; Murata M;
Pediatr Blood Cancer; 2015 Feb; 62(2):291-298. PubMed ID: 25307105
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus clearance is age-dependent within the pediatric population.
Przepiorka D; Blamble D; Hilsenbeck S; Danielson M; Krance R; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(6):601-5. PubMed ID: 11041564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
